TY - JOUR
T1 - Development of a small implantable right ventricular assist device
AU - Fukamachi, Kiyotaka
AU - Horvath, David J.
AU - Massiello, Alex L.
AU - Ootaki, Yoshio
AU - Kamohara, Keiji
AU - Akiyama, Masatoshi
AU - Zahr, Firas
AU - Kopcak, Michael W.
AU - Dessoffy, Raymond
AU - Chen, Ji Feng
AU - Benefit, Stephen
AU - Golding, Leonard A.R.
PY - 2005/11
Y1 - 2005/11
N2 - The purpose of this program is to design, develop, and clinically evaluate a new, implantable right ventricular assist device (RVAD) that can be used as a component of an implantable biventricular assist device for patients with severe biventricular heart failure. The initial phase of this program resulted in a prototype RVAD, named DexAide, a modified version of the CorAide left ventricular assist device. In vitro testing was performed in a stand-alone circuit and in a true RVAD mode to evaluate pump performance. Pump flow and power were measured under various afterload and pump speed conditions. The pump performance requirements of 2 to 6 l/min and a pressure rise of 20 to 60 mm Hg were successfully met with pump speeds between 1,800 and 3,200 rpm. The nominal design point of 4 l/min and 40 mm Hg pressure rise was achieved at 2,450 ± 70 rpm with a power consumption of 3.0 ± 0.2 W. The initial in vitro testing met the design criteria for the new DexAide RVAD. Initial in vivo testing is under way, which will be followed by preclinical readiness testing and a pilot clinical trial in this 5-year program.
AB - The purpose of this program is to design, develop, and clinically evaluate a new, implantable right ventricular assist device (RVAD) that can be used as a component of an implantable biventricular assist device for patients with severe biventricular heart failure. The initial phase of this program resulted in a prototype RVAD, named DexAide, a modified version of the CorAide left ventricular assist device. In vitro testing was performed in a stand-alone circuit and in a true RVAD mode to evaluate pump performance. Pump flow and power were measured under various afterload and pump speed conditions. The pump performance requirements of 2 to 6 l/min and a pressure rise of 20 to 60 mm Hg were successfully met with pump speeds between 1,800 and 3,200 rpm. The nominal design point of 4 l/min and 40 mm Hg pressure rise was achieved at 2,450 ± 70 rpm with a power consumption of 3.0 ± 0.2 W. The initial in vitro testing met the design criteria for the new DexAide RVAD. Initial in vivo testing is under way, which will be followed by preclinical readiness testing and a pilot clinical trial in this 5-year program.
UR - http://www.scopus.com/inward/record.url?scp=33644874425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644874425&partnerID=8YFLogxK
U2 - 10.1097/01.mat.0000181031.66900.b6
DO - 10.1097/01.mat.0000181031.66900.b6
M3 - Article
C2 - 16340358
AN - SCOPUS:33644874425
VL - 51
SP - 730
EP - 735
JO - ASAIO Journal
JF - ASAIO Journal
SN - 1058-2916
IS - 6
ER -